This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaFocus: Vaccine Adjuvants In Infectious Disease

NEW YORK, April 11, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaFocus: Vaccine Adjuvants in Infectious Disease

PharmaFocus: Vaccine Adjuvants in Infectious Disease


Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry's "dirty little secret". Today, vaccine adjuvants are credited with helping to bolster the immune response in the host post-vaccination. Recently, second-generation adjuvants have come under scrutiny after reports that the adjuvant used in certain pandemic influenza vaccines was linked to causing narcolepsy in Swedish and British adults. Such reports, compounded by the general mistrust of adjuvants, have resulted in these vital vaccine components becoming the scapegoat of the vaccine industry. However, immunologists and infectious disease specialists are in agreement over the beneficial uses of adjuvants in vaccines today, especially as a means to reduce the number of doses, increase the likelihood of a sustained immunological response and decrease the overall incidence of disease. Scope

- Overview of vaccine adjuvants, including the host immune system, host cell targets, descriptions of different adjuvant classes and regulatory guidelines to seek approval for adjuvanted vaccines.

- Key topics covered include vaccines and the host immune response, adjuvant targets, and current adjuvant options (first and second generation) for the vaccine adjuvant market.

- Analysis of the current and future market competition in the vaccine adjuvant market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global vaccine adjuvant market.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs